Search - tctmd.com

Presenter: Mitchell W. Krucoff, David R. Rutledge, Vivian W. Mao, Weiying Zhao, Alena V. Pechonkina, Jin Wang, Lalitha K. Jonnavithula, Krishnankutty Sudhir, James B. Hermiller

January 03, 2012

Presentation TCT 2012

Prospective Evaluation Of the Xience V Everolimus-Eluting Stent In Saphenous Vein Graft Atherosclerosis: the Xience V-SVG Angiographic Study.

Presenter: Emmanouil S. Brilakis, Aristotelis C. Papayannis, Abdul-rahman R. Abdel-karim, Tesfaldet T. Michael, Arif Mahmood, Lorenza B. Makke, Michele Roesle, Donald Haagen, Bavana V. Rangan, Subhash Banerjee

January 03, 2012

News Daily News

Elevated CRP—But Not High Platelet Reactivity—Predictive After DES

December 04, 2011

Advertisement

BIOSOLVE-1 Shows Improvement in Paclitaxel-Eluting Bioabsorbable Stent

Real-World Equivalence Seen for Zotarolimus- and Everolimus-Eluting Stents

Los Balones liberadores de Fármacos arrojan Resultados Positivos en el Tratamiento de la Reestenosis intra stent

Drug-eluting Balloons Show Positive Results in Treating In-stent Restenosis

Korean Registry Confirms Edge of Everolimus- Over Zotarolimus-Eluting Stents

OCTOPUS Looks at Vessel Healing After DES vs. BMS Plus Paclitaxel Balloon

Survey Reveals Improvements, Gaps in Primary PCI Access Across Europe

Boston Scientific Receives FDA Approval for 32 MM and 38 MM Lengths for PROMUS Element™ Plus Platinum Chromium Stent System

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

Biolimus-Eluting Stents Perform Well in STEMI, Unselected Populations

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

TCTMD’s Top 10 Most Popular News Stories From 2011

Experts Give Their Picks for Most Important Developments of 2011

Study Finds No ‘Obesity Paradox’ in DES-Treated Patients

Stent Thrombosis Risk Lower with Xience vs. First-Generation DES

El Riesgo de Trombosis del Stent es Menor con Xience que con SLF de 1ª Generación

NEXT Up: Polymer-Free SES Angiographically Superior to Taxus

Safety and Effectiveness of Everolimus-Eluting Stents in 5054 Patients from a Large, Prospective, Real World Study: Two-Year Clinical Outcomes from the XIENCE V® USA Study.

Prospective Evaluation Of the Xience V Everolimus-Eluting Stent In Saphenous Vein Graft Atherosclerosis: the Xience V-SVG Angiographic Study.

Elevated CRP—But Not High Platelet Reactivity—Predictive After DES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content